- A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia
Journal of Hypertension · 2026
- Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.
2026
- Abnormal Lipid Signaling Characterizes Diastolic Dysfunction in Pediatric Cardiomyopathy
JACC Basic to Translational Science · 2026
- Clinical Impact of Semaglutide Beyond Glycemic Control: A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity
Pharmaceuticals · 2026
- Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation
EP Europace · 2026
- The effects of sacubitril/valsartan compared to valsartan in experimentally induced chronic kidney disease
Naunyn-Schmiedeberg s Archives of Pharmacology · 2026
- Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults
JAMA Cardiology · 2026
- Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: A cost‐effectiveness modelling study
Diabetes Obesity and Metabolism · 2026
- Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes
JAMA Internal Medicine · 2026
- Evaluating Semaglutide’s Protection in H/R - Injured AC16 Cardiomyocytes: Oxidative Stress, Inflammation, Apoptosis, and Autophagy Insights
International Journal of General Medicine · 2026
- Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials
European journal of medical research · 2026
- Comparative effectiveness of sleeve gastrectomy and semaglutide for weight loss and metabolic outcomes: a prospective non-randomized study
BMC Medicine · 2026
- Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial
PharmacoEconomics · 2026
- Semaglutide Augments Vascular Proliferation and Cardiac Performance in a Large Animal Model of Ischemic Cardiomyopathy
American Journal of Physiology-Heart and Circulatory Physiology · 2026
- Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study
Diabetes Research and Clinical Practice · 2026
- Prevalence of obstructive coronary artery disease in asymptomatic cancer patients with elevated troponin levels
Cardio-Oncology · 2026
- Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes
Diabetes Obesity and Metabolism · 2026
- Kinesiophobia in Patients With Angina Pectoris: A Latent Profile Analysis
The Journal of Cardiovascular Nursing · 2026
- Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( <scp>STEER</scp> )
Diabetes Obesity and Metabolism · 2026
- Semaglutide preserves myocardial function in a murine model of sequential anthracycline trastuzumab induced early cardiotoxicity: insights from speckle tracking echocardiography
European Heart Journal - Cardiovascular Imaging · 2026
- Semaglutide-induced transient intestinal ischemia: A case report
International Journal of Clinical Pharmacology and Therapeutics · 2025
- Correction to “Clinical Profiles and In‐Hospital Outcomes of Pre‐Existing Versus Newly Diagnosed Atrial Fibrillation in Coronary Care Units: Insights From the <scp>MORCOR</scp> ‐ <scp>TURK</scp> National Registry”
Journal of Arrhythmia · 2025
- Association of oral semaglutide with cardiovascular outcomes in a real‐world primary prevention population
Diabetes Obesity and Metabolism · 2025
- Neurological Complications in Surgical Patients with Left-Sided Infective Endocarditis: Risk Factors, Prognosis, and Surgical Timing
Journal of Cardiovascular Development and Disease · 2025
- Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study
Cureus · 2025
- Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease
JAMA Cardiology · 2025
- Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols
Cureus · 2025
- Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW
Cardiovascular Diabetology · 2025
- ANALYSIS OF ADVANTAGES AND DISADVANTAGES OF MODERN HYPOGLYCEMIC DRUGS
Oriental Journal of Medicine and Pharmacology · 2025
- Uterine Fibroids-Associated GWAS Loci and the Risk of Arterial Hypertension: A Pilot Study
Frontiers in Bioscience-Scholar · 2025
- GLP-1 agonist, Semaglutide in acute pulmonary embolism recovery: a four week proof-of-concept study including proteomic profiling
European Heart Journal Open · 2025
- Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials
BMC Cardiovascular Disorders · 2025
- Effectiveness of Telemedicine Prescribing and a Long‐Acting Obesity Medication Behavioral Program: A 24‐Week Single‐Arm Study
Obesity · 2025
- Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study
Obesity Surgery · 2025
- Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure
Biomolecules · 2025
- REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide
Kidney International · 2025
- The impact of GLP-1 receptor agonists on cognitive decline in heart failure patients: a retrospective cohort study using real world data
European Heart Journal · 2025
- Newer GLP-1 receptor agonists and clinical outcomes in heart failure with reduced ejection fraction: a real-world comparative study
European Heart Journal · 2025
- Impact of body mass index and prediabetes on the risk of type 2 diabetes and cardiovascular events following a recent myocardial infarction
European Heart Journal · 2025
- Cell-type specific secretome profiling reveals targets of liver-heart interorgan crosstalk in HFpEF and semaglutide treatment
European Heart Journal · 2025
- Head to head comparison of semaglutide and colchicine for treating atrial remodeling in post-MI rats with reduced ejection fraction
European Heart Journal · 2025
- Adipose and non-adipose layers of epicardium: paracrine activity consequences on cardiomyocytes and modulation by semaglutide
European Heart Journal · 2025
- Effect of semaglutide in patients with type 2 diabetes and peripheral artery disease: an analysis of the STRIDE trial stratified by disease severity and age
European Heart Journal · 2025
- Differential released proteins between epicardial and subcutaneous fat from patients with cardiovascular disease: role on its progression and semaglutide modulation
European Heart Journal · 2025
- Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial
European Heart Journal · 2025
- NLRP3/IL-1 pathway was reduced by semaglutide and dapagliflozin in association therapy under exposure to anthracyclines in hyperglycemic conditions
European Heart Journal · 2025
- 5-year risk of progression to type 2 diabetes in patients with myocardial infarction and overweight or obesity: a cohort study of the preventive potential of semaglutide treatment
European Heart Journal · 2025
- Liraglutide in patients with heart failure with preserved ejection fraction and obesity without diabetes
European Heart Journal · 2025
- Identification of patients eligible for treatment with semaglutide after an acute coronary syndrome according to guidelines recommendations
European Heart Journal · 2025
- Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial
European Heart Journal · 2025